PeptiVAX

PeptiVAX is an experimental **peptide-based SARS-CoV-2 vaccine platform** developed by researchers at the University of Helsinki and associated institutions. It was created by adapting the PeptiCRAd concept, in which selected antigenic peptides are decorated onto an adenoviral delivery backbone, to generate a **cytotoxic T lymphocyte focused vaccine** intended to broaden antiviral immunity beyond spike-only approaches. The platform is designed to deliver multiple **conserved CD8 T-cell epitopes** from coronavirus proteins, including non-spike antigens, with the goal of inducing cellular immune responses that may be more resilient to viral evolution and spike mutations. Based on the provided context, PeptiVAX is a preclinical vaccine platform for prevention of COVID-19 caused by SARS-CoV-2 and is positioned as a rapidly adaptable vaccine design strategy.

Other names

PeptiVAX